NASDAQ:SEPN

Septerna Q2 2026 Earnings Results & Report

Septerna logo
$41.67 -0.93 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.02 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.29 versus the -$0.4260 consensus estimate, while revenue of $26.75 million topped the $19.22 million estimate by $7.52 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Septerna EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.4260
Beat/Miss
Beat by +$0.1360
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Septerna Revenue Results

Actual Revenue
$26.75 million
Expected Revenue
$19.22 million
Beat/Miss
Beat by +$7.52 million
YoY Revenue Growth
N/A

Septerna Q2 2026 Earnings FAQ

Septerna (NASDAQ:SEPN) reported earnings of -$0.29 per share for Q2 2026, beating the consensus estimate of -$0.4260. The report was announced on Monday, August 10, 2026.

Septerna reported revenue of $26.75 million for Q2 2026, against a consensus estimate of $19.22 million.

Septerna Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Septerna (NASDAQ:SEPN) Director Sells $3,934,723.80 in Stock
Septerna FY2026 Earnings Forecast Lowered by HC Wainwright
Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development. The company has also pursued collaborations to apply its GPCR discovery capabilities to additional therapeutic programs.

View Septerna Profile